Read our recent announcements about our company, our research, and partnerships.
High-profile publication in leading journal "Autism Research" validates BlinkLab’s technology, providing support for future clinical adoption
BlinkLab announces Rush as eighth premier U.S. autism center for F1DA 510(k) trial of smartphone-based diagnostic aid, with first expected subjects in Q1 2026.
BlinkLab Dx 1 achieved 83.7% sensitivity and 84.7% specificity in a clinically diverse pediatric population, confirming robust real-world diagnostic performance.
Marking another step toward FDA clearance for its autism diagnostic tool.
Partnerships with Leading Pediatric Institutions Strengthen BlinkLab’s U.S. Trial Network
BlinkLab onboards Ivy League institution Perelman School as Third Clinical Site for its FDA 510(k) Diagnostic Trial
Let's make developmental diagnostic evaluation more efficient and accessible.
Stay up to date with the latest developments of our product!
You will receive our newsletter. You can opt out via the newsletter.
%20SMALL.jpg)
